Allergies & Asthma

While criteria for contraindication to COVID-19 mRNA vaccines are narrow, more observation or possibly delayed vaccination may be necessary in those with a history of severe allergic reactions, CDC staff said on a call with clinicians on Friday. The only individuals who should not receive mRNA COVID-19 vaccines, such as the recently authorized Pfizer/BioNTech vaccine
0 Comments
It’s no secret that there’s a lot of wasteful spending in healthcare, and patients have become increasingly frustrated by this as their insurance premiums have skyrocketed. Yet unnecessary procedures are still performed every day in the U.S. — and sometimes patients are harmed as a result. MedPage Today‘s Enterprise & Investigative Reporting team needs your
0 Comments
New therapies and devices for chronic obstructive pulmonary disease (COPD) were approved in 2020 and researchers continued to explore expanding the definition of disease beyond spirometry. But 2020 was dominated by the struggles managing the care of highly vulnerable COPD patients during the COVID-19 pandemic. COVID Paradox The delivery of routine components of COPD care,
0 Comments
“While doctors have long believed that dementia presents in the checkbook, our study helps show that these financial symptoms are common and span years before and after diagnosis.” — Lauren Hersch Nicholas, PhD, MPP, of Johns Hopkins University in Baltimore, on research showing difficulties with finances were evident long before dementia diagnosis. “Hospitals, they want
0 Comments
New guidelines from the National Asthma Education and Prevention Program (NAEPP) of the National Heart, Lung, and Blood Institute (NHLBI) — the agency’s first update since 2007 — take account of new management options including single maintenance and reliever therapy (SMART) and long-acting muscarinic antagonists (LAMAs). As has long been standard practice, the foundation for
0 Comments
Note that some links may require registration or subscription. Pfizer and BioNTech announced emergency authorization from the United Kingdom for their COVID-19 vaccine on Wednesday. Meanwhile, White House Chief of Staff Mark Meadows invited FDA Commissioner Stephen Hahn, MD, to come explain why his agency hasn’t yet granted an emergency use authorization (EUA) for Pfizer’s
0 Comments
Omalizumab (Xolair) maintained efficacy for chronic rhinosinusitis with nasal polyps, a researcher reported. In an open-label extension study of two, 24-week clinical trials, omalizumab was associated with significant improvements in nasal polyp scores (mean change -0.97, 95% CI -1.25 to -0.69), nasal congestion scores (mean change -0.99, 95% CI -1.14 to -0.83), and Sino-Nasal Outcome
0 Comments
Treatment with the investigational anti-IgE biologic ligelizumab was generally effective in patients with H1 antihistamine-unresponsive chronic spontaneous urticaria (CSU) who did not achieve complete symptom control with omalizumab (Xolair), an exploratory analysis of a phase IIb extension study showed. In a subset of omalizumab-treated patients with a score greater than 0 on the 7-day urticaria
0 Comments
Switching to telemedicine for routine asthma visits in the early months of the COVID-19 pandemic was linked with positive disease control and an increase in appointment “show rates” among Los Angeles inner city children, a researcher reported. Delivery of routine asthma care via telemedicine did not appear to negatively impact asthma control among the children
0 Comments
The investigational monoclonal antibody tezepelumab proved to be an effective therapy for uncontrolled severe asthma in patients with and without perennial and seasonal allergies, a post-hoc analysis of data from the phase II PATHWAY study found. The subgroup analysis focused on patients who did and did not have baseline sensitivity to perennial allergens such as
0 Comments